
EVOCAL Health is a biopharmaceutical digital health company pioneering the use of the human voice as a biomarker for health and longevity. The company develops clinically-proven digital diagnostic and therapeutic concepts leveraging Vocal Biomarkers and AI to prevent, predict, and manage diseases. Their CE-certified, device-agnostic platform supports remote patient monitoring and decentralized clinical trials, collaborating with biopharmaceutical companies, research institutions, and healthcare providers. EVOCAL Health focuses on cardiovascular, neurodegenerative, respiratory diseases, and vital condition detection, aiming to extend health span and improve patient care with innovative, cost-effective voice-based diagnostics and therapies. The company is recognized as one of Europe's most innovative startups and operates regional hubs in Germany and the USA.

EVOCAL Health is a biopharmaceutical digital health company pioneering the use of the human voice as a biomarker for health and longevity. The company develops clinically-proven digital diagnostic and therapeutic concepts leveraging Vocal Biomarkers and AI to prevent, predict, and manage diseases. Their CE-certified, device-agnostic platform supports remote patient monitoring and decentralized clinical trials, collaborating with biopharmaceutical companies, research institutions, and healthcare providers. EVOCAL Health focuses on cardiovascular, neurodegenerative, respiratory diseases, and vital condition detection, aiming to extend health span and improve patient care with innovative, cost-effective voice-based diagnostics and therapies. The company is recognized as one of Europe's most innovative startups and operates regional hubs in Germany and the USA.
Founded: 2020
Headquarters: Hamburg, Germany
Tech: AI-driven vocal biomarker platform (voice, breathing, cough)
Regulatory: CE-certified product (May 2021)
Funding: Non-equity assistance grants in 2021
Remote patient monitoring, digital diagnostics and therapeutics for respiratory, cardiovascular, and neurodegenerative/mental diseases.
2020
Biotechnology
Initial non-equity assistance/grant-style support announced Feb 25, 2021.
Additional non-equity assistance round announced Oct 6, 2021 involving accelerator/partner organizations.